Total Payments
$3.0M
2024 Payments
$458,120
Companies
2
Transactions
89
Payment Breakdown by Category
Consulting$3.0M (99.9%)
Travel$1,389 (0.0%)
Research$493.48 (0.0%)
Food & Beverage$167.40 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3.0M | 66 | 99.9% |
| Travel and Lodging | $1,389 | 9 | 0.0% |
| Unspecified | $493.48 | 7 | 0.0% |
| Food and Beverage | $167.40 | 7 | 0.0% |
Payments by Type
General
$3.0M
82 transactions
Research
$493.48
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $3.0M | 87 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $98.47 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $458,120 | 28 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($458,120) |
| 2023 | $419,688 | 12 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($419,688) |
| 2022 | $680,000 | 13 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($680,000) |
| 2021 | $761,388 | 14 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($761,388) |
| 2020 | $685,100 | 13 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($685,100) |
| 2019 | $87.45 | 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($87.45) |
| 2018 | $406.03 | 6 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($406.03) |
| 2017 | $98.47 | 2 | BioMarin Pharmaceutical Inc. ($98.47) |
All Payment Transactions
89 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $29,112.50 | General |
| 12/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $28,475.00 | General |
| 11/14/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $30,387.50 | General |
| 11/05/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $8,925.00 | General |
| 09/19/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $31,662.50 | General |
| 09/19/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $25,925.00 | General |
| 08/05/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $44,200.00 | General |
| 07/08/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $28,900.00 | General |
| 05/30/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $35,700.00 | General |
| 05/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $49,087.50 | General |
| 03/26/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $29,750.00 | General |
| 03/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $28,475.00 | General |
| 02/16/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $40,587.50 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $45,475.00 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,140.53 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $64.00 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $39.00 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $36.00 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $36.00 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | Cash or cash equivalent | $33.26 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $27.00 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $20.00 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $18.99 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | Cash or cash equivalent | $16.30 | General |
| 02/06/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | Cash or cash equivalent | $10.87 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A SINGLE-DOSE, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED CROSSOVER TRIAL TO EVALUATE THE ABUSE POTENTIAL OF CENTANAFADINE EB-1020 IMMEDIATE RELEASE IN HEALTHY ADULT RECREATIONAL DRUG USERS WITH STIMULANT EXPERIENCE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $493.48 | 7 |
About Dr. Bruce Berger, M.D
Dr. Bruce Berger, M.D is a Internal Medicine healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/14/2012. The National Provider Identifier (NPI) number assigned to this provider is 1821361395.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Berger, M.D has received a total of $3.0M in payments from pharmaceutical and medical device companies, with $458,120 received in 2024. These payments were reported across 89 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($3.0M).
Ad
Practice Information
- Specialty Internal Medicine
- Location Brooklyn, NY
- Active Since 02/14/2012
- Last Updated 02/06/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1821361395
Products in Payments
- BMN 190 (Biological) $98.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Brooklyn
Dr. Jesi Ramone, Md, MD
Internal Medicine — Payments: $701,491
Internal Medicine $701,491
Dr. Ali El Atat, M.d, M.D
Internal Medicine — Payments: $426,309
Internal Medicine $426,309
Manish Parikh, Md, MD
Internal Medicine — Payments: $360,332
Internal Medicine $360,332
Dr. Samuel Uter, Md, MD
Internal Medicine — Payments: $238,375
Internal Medicine $238,375
Dr. Bharath Reddy, Md, MD
Internal Medicine — Payments: $159,733
Internal Medicine $159,733
Sima Muster
Internal Medicine — Payments: $137,530
Internal Medicine $137,530